Product Description
Mechanisms of Action: GABA Modulator
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Chile | Colombia | Czech | Dominican Republic | Germany | Hungary | Ireland | Italy | Lithuania | Pakistan | Poland | Portugal | Romania | Russia | Slovakia | Slovenia | Spain | Taiwan | Turkey | Venezuela
Approved Indications: None
Known Adverse Events: None
Company: CM Chungmu Hospital
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|